ATXS
Price
$4.22
Change
-$0.18 (-4.09%)
Updated
May 9, 04:59 PM (EDT)
Capitalization
249.44M
94 days until earnings call
FOLD
Price
$5.99
Change
-$0.09 (-1.48%)
Updated
May 9, 04:59 PM (EDT)
Capitalization
1.87B
83 days until earnings call
Ad is loading...

ATXS vs FOLD

Header iconATXS vs FOLD Comparison
Open Charts ATXS vs FOLDBanner chart's image
Astria Therapeutics
Price$4.22
Change-$0.18 (-4.09%)
Volume$13.2K
Capitalization249.44M
Amicus Therapeutics
Price$5.99
Change-$0.09 (-1.48%)
Volume$220.5K
Capitalization1.87B
ATXS vs FOLD Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. FOLD commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and FOLD is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (ATXS: $4.40 vs. FOLD: $6.08)
Brand notoriety: ATXS and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 211% vs. FOLD: 239%
Market capitalization -- ATXS: $249.44M vs. FOLD: $1.87B
ATXS [@Biotechnology] is valued at $249.44M. FOLD’s [@Biotechnology] market capitalization is $1.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while FOLD’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • FOLD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ATXS and FOLD are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -14.73% price change this week, while FOLD (@Biotechnology) price change was -8.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.32%. For the same industry, the average monthly price growth was +9.54%, and the average quarterly price growth was -14.72%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

FOLD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-6.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($1.87B) has a higher market cap than ATXS($249M). FOLD YTD gains are higher at: -35.456 vs. ATXS (-50.783). FOLD has higher annual earnings (EBITDA): 29.4M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. FOLD (250M). ATXS has less debt than FOLD: ATXS (5.35M) vs FOLD (444M). FOLD has higher revenues than ATXS: FOLD (528M) vs ATXS (0).
ATXSFOLDATXS / FOLD
Capitalization249M1.87B13%
EBITDA-111.56M29.4M-379%
Gain YTD-50.783-35.456143%
P/E RatioN/AN/A-
Revenue0528M-
Total Cash328M250M131%
Total Debt5.35M444M1%
FUNDAMENTALS RATINGS
ATXS vs FOLD: Fundamental Ratings
ATXS
FOLD
OUTLOOK RATING
1..100
257
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9393
PRICE GROWTH RATING
1..100
9191
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a34

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (61) in the Biotechnology industry is in the same range as FOLD (68). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FOLD (100). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

ATXS's SMR Rating (93) in the Biotechnology industry is in the same range as FOLD (93). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

ATXS's Price Growth Rating (91) in the Biotechnology industry is in the same range as FOLD (91). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as FOLD (100). This means that ATXS’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSFOLD
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 10 days ago
70%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 3 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DHIIX18.41N/A
N/A
Diamond Hill International I
CGLAX16.57N/A
N/A
Calvert Global Equity Fund Class A
FMIHX14.56N/A
N/A
FMI Large Cap Investor
HAGIX73.45N/A
N/A
Carillon Eagle Mid Cap Growth I
DGIFX22.56N/A
N/A
Disciplined Growth Investors

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-0.45%
KYMR - ATXS
54%
Loosely correlated
+5.70%
TRDA - ATXS
53%
Loosely correlated
+5.64%
APGE - ATXS
51%
Loosely correlated
+7.29%
XENE - ATXS
50%
Loosely correlated
+0.59%
CRNX - ATXS
50%
Loosely correlated
+4.17%
More